6 results on '"Mari, Andrea"'
Search Results
2. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature
- Author
-
Mari, Andrea, Campi, Riccardo, Tellini, Riccardo, Gandaglia, Giorgio, Albisinni, Simone, Abufaraj, Mohammad, Hatzichristodoulou, Georgios, Montorsi, Francesco, van Velthoven, Roland, Carini, Marco, Minervini, Andrea, and Shariat, Shahrokh F.
- Published
- 2017
- Full Text
- View/download PDF
3. Impact of smoking on urologic cancers: a snapshot of current evidence.
- Author
-
Kumar, Raj, Matulewicz, Richard, Mari, Andrea, Moschini, Marco, Ghodoussipour, Saum, Pradere, Benjamin, Rink, Michael, Autorino, Riccardo, Desai, Mihir M., Gill, Inderbir, and Cacciamani, Giovanni E.
- Subjects
SMOKING cessation ,SMOKING ,PROSTATE cancer ,BLADDER cancer ,TOBACCO smoke ,DISEASE relapse ,LYMPHATIC metastasis - Abstract
Purpose: The purpose of this paper is to present evidence regarding the associations between smoking and the following urologic cancers: prostate, bladder, renal, and upper tract urothelial cancer (UTUC). Methods: This is a narrative review. PubMed was queried for evidence-based analyses and trials regarding the associations between smoking and prostate, bladder, renal, and UTUC tumors from inception to September 1, 2022. Emphasis was placed on articles referenced in national guidelines and protocols. Results: Prostate—multiple studies associate smoking with higher Gleason score, higher tumor stage, and extracapsular invasion. Though smoking has not yet been linked to tumorigenesis, there is evidence that it plays a role in biochemical recurrence and cancer-specific mortality. Bladder—smoking is strongly associated with bladder cancer, likely due to DNA damage from the release of carcinogenic compounds. Additionally, smoking has been linked to increased cancer-specific mortality and higher risk of tumor recurrence. Renal—smoking tobacco has been associated with tumorigenesis, higher tumor grade and stage, poorer mortality rates, and a greater risk of tumor recurrence. UTUC—tumorigenesis has been associated with smoking tobacco. Additionally, more advanced disease, higher stage, lymph node metastases, poorer survival outcomes, and tumor recurrence have been linked to smoking. Conclusion: Smoking has been shown to significantly affect most urologic cancers and has been associated with more aggressive disease, poorer outcomes, and tumor recurrence. The role of smoking cessation is still unclear, but appears to provide some protective effect. Urologists have an opportunity to engage in primary prevention by encouraging cessation practices. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.
- Author
-
Lonati, Chiara, Afferi, Luca, Mari, Andrea, Minervini, Andrea, Krajewski, Wojciech, Borghesi, Marco, Schulz, Gerald B., Rink, Michael, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, Martini, Alberto, Necchi, Andrea, Contieri, Roberto, Hurle, Rodolfo, Umari, Paolo, Zamboni, Stefania, Simeone, Claudio, Soria, Francesco, and Marra, Giancarlo
- Subjects
BLADDER cancer ,CYSTECTOMY ,PROGRESSION-free survival ,LOG-rank test ,IMMUNOTHERAPY - Abstract
Purpose: To compare cancer-specific mortality (CSM) and overall mortality (OM) between immediate radical cystectomy (RC) and Bacillus Calmette–Guérin (BCG) immunotherapy for T1 squamous bladder cancer (BCa). Methods: We retrospectively analysed 188 T1 high-grade squamous BCa patients treated between 1998 and 2019 at fifteen tertiary referral centres. Median follow-up time was 36 months (interquartile range: 19–76). The cumulative incidence and Kaplan–Meier curves were applied for CSM and OM, respectively, and compared with the Pepe–Mori and log-rank tests. Multivariable Cox models, adjusted for pathological findings at initial transurethral resection of bladder (TURB) specimen, were adopted to predict tumour recurrence and tumour progression after BCG immunotherapy. Results: Immediate RC and conservative management were performed in 20% and 80% of patients, respectively. 5-year CSM and OM did not significantly differ between the two therapeutic strategies (Pepe–Mori test p = 0.052 and log-rank test p = 0.2, respectively). At multivariable Cox analyses, pure squamous cell carcinoma (SqCC) was an independent predictor of tumour progression (p = 0.04), while concomitant lympho-vascular invasion (LVI) was an independent predictor of both tumour recurrence and progression (p = 0.04) after BCG. Patients with neither pure SqCC nor LVI showed a significant benefit in 3-year recurrence-free survival and progression-free survival compared to individuals with pure SqCC or LVI (60% vs. 44%, p = 0.04 and 80% vs. 68%, p = 0.004, respectively). Conclusion: BCG could represent an effective treatment for T1 squamous BCa patients with neither pure SqCC nor LVI, while immediate RC should be preferred among T1 squamous BCa patients with pure SqCC or LVI at initial TURB specimen. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes.
- Author
-
Krajewski, Wojciech, Moschini, Marco, Chorbińska, Joanna, Nowak, Łukasz, Poletajew, Sławomir, Tukiendorf, Andrzej, Afferi, Luca, Teoh, Jeremy Yuen-Chun, Muilwijk, Tim, Joniau, Steven, Tafuri, Alessandro, Antonelli, Alessandro, Cianflone, Francesco, Mari, Andrea, Di Trapani, Ettore, Hendricksen, Kees, Alvarez-Maestro, Mario, Rodríguez-Serrano, Andrea, Simone, Giuseppe, and Zamboni, Stefania
- Subjects
BLADDER cancer ,SURVIVAL rate ,URETHRA ,DISEASE relapse ,IMMUNOTHERAPY ,REGRESSION analysis ,LOG-rank test - Abstract
Purpose: This study was carried out to assess whether a prolonged time between primary transurethral resection of non-muscle-invasive bladder cancer (TURB) and implementation of bacillus Calmette–Guerin (BCG) immunotherapy (time to BCG; TTBCG) is associated with adverse oncological survival in patients with T1 high-grade (HG) non-muscle-invasive bladder cancer (NMIBC). Materials and methods: Data on 429 patients from 13 tertiary care centers with primary T1HG NMIBC treated with reTURB and maintenance BCG between 2001 and 2019 were retrospectively reviewed. Change-point regression was applied following Muggeo's approach. The population was divided into subgroups according to TTBCG, whereas the recurrence-free survival (RFS) and progression-free survival (PFS) were estimated with log-rank tests. Additionally, Cox regression analyses were performed. Due to differences in baseline patient characteristics, propensity-score-matched analysis (PSM) and inverse-probability weighting (IPW) were implemented. Results: The median TTBCG was 95 days (interquartile range (IQR): 71–127). The change-point regression analysis revealed a gradually increasing risk of recurrence with growing TTBCG. The risk of tumor progression gradually increased until a TTBCG of approximately 18 weeks. When the study population was divided into two subgroups (time intervals: ≤ 101 and > 101 days), statistically significant differences were found for both RFS (p = 0.029) and PFS (p = 0.005). Furthermore, in patients with a viable tumor at reTURB, there were no differences in RFS and PFS. After both PSM and IPW, statistically significant differences were found for both RFS and PFS, with worse results for longer TTBCG. Conclusion: This study shows that delaying BCG immunotherapy after TURB of T1HG NMIBC is associated with an increased risk of tumor recurrence and progression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature.
- Author
-
Mari, Andrea, Campi, Riccardo, Tellini, Riccardo, Gandaglia, Giorgio, Albisinni, Simone, Abufaraj, Mohammad, Hatzichristodoulou, Georgios, Montorsi, Francesco, van Velthoven, Roland, Carini, Marco, Minervini, Andrea, and Shariat, Shahrokh F.
- Subjects
- *
CANCER relapse , *CYSTECTOMY , *BLADDER cancer treatment , *LYMPHADENECTOMY , *HEALTH outcome assessment - Abstract
Purpose: To review the currently available literature reporting the patterns of recurrence and their predictive factors after open radical cystectomy (RC) for bladder cancer.Methods: A review of the literature was performed using the MEDLINE, Scopus and Web of Sciences databases from January 1997 to May 2017. The PRISMA guidelines were followed for the conduct of the study.Results: Local recurrence rate ranges between 30 and 54%. Distant recurrence is not often standardized and is reported in up to 50% of cases. The overall 5-year recurrence-free survival rates from 58 to 81%. The mean follow-up of studies included in the analysis ranged from 18 to 350 months. Details on the most important demographic and epidemiological, clinical, histologic and pathologic predictors of recurrence after radical cystectomy are provided through an evidence-based approach. The impact of the extension of lymph node dissection on recurrence after RC is investigated.Conclusions: A correct prognostic assessment is essential for patients undergoing radical cystectomy for bladder cancer, thereby potentially improving their oncologic outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.